化合物 SBI-0640756|T5173|TargetMol

SBI-0640756
1821280-29-8

￥239 1mg 起订

￥666 5mg 起订

￥1060 10mg 起订

上海更新日期：2024-09-29

TargetMol中国（陶术生物）

VIP3年

联系人：邵小姐

手机：4008200310 拨打

邮箱：marketing@tsbiochem.com

产品详情:

中文名称：: 化合物 SBI-0640756

英文名称：: SBI-0640756

CAS号：: 1821280-29-8

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 99.75%

产品类别：: 抑制剂

货号：: T5173

Product Introduction

Bioactivity

Name	SBI-0640756
Description	SBI-0640756 (SBI-756) (SBI-756) is a first-in-class inhibitor that targets eIF4G1 and disrupts the eIF4F complex.
Cell Research	Cells were rinsed with PBS and lysed as previously described. Protein concentration was determined using Coomassie Plus Protein Assay Reagent. Equal amounts of cell lysate proteins (50 μg) were separated on SDS-PAGE and transferred to polyvinylidene difluoride membranes. Membranes were blocked (5% BSA/TBST, 1 h) and incubated with primary antibodies (1 h at room temperate or overnight at 4°C), with shaking. Following three TBST washes, membranes were incubated for 1 h at room temperature secondary antibodies (1:10,000). Detection and quantifications were made using Odyssey Infrared Imaging System, or by exposing them to X-ray film. Antibodies against p-AKT, p-PRAS40, p-IKK, p-IκB, p-TSC, p-mTOR, p-p70S6K, p-RPS6, p-4E-BP1, pSGK3, AKT, PRAS40, IKK, IκB, mTOR, p70S6K, RPS6, 4E-BP1, GSK3, eIF4G1, and eIF4E were purchased from Cell Signaling Technology. Antibodies against β-actin and α-tubulin were obtained from Santa Cruz Biotechnology. Secondary antibodies were goat anti-rabbit Alexa-680 F(ab')2 and goat anti-mouse IRDye 800 F(ab')2. All antibodies were used according to the suppliers' recommendations.
In vitro	SBI-0640756有效地以剂量依赖的方式使eIF4G1与eIF4E解离，伴随着4E-BP1:eIF4E结合的同时增加，反映了eIF4F复合体形成受损。SBI-0640756还抑制了AKT/mTORC1信号传导，并且mTORC1的抑制通过激活4E-BPs破坏eIF4F复合体。尽管torin1在WT中诱导eIF4G1与eIF4E的解离，但在4E-BP DKO MEFs中并没有此效果，SBI-0640756在WT和4E-BP DKO MEFs中均降低了eIF4G1:eIF4E的关联。同样，SBI-0640756而非torin1降低了E1A/RAS转化的4E-BP DKO MEFs的增殖。
In vivo	在Ink4a 基因失活并诱导NRasQ61E后11周开始仅施用SBI-0640756（大约在肿瘤出现前10-14天），与对照组未经治疗的动物相比，能够延迟肿瘤发生时间（从20-26周开始）并且将肿瘤发生率降低了50%。对于已经形成的肿瘤，仅使用BRAFi治疗或BRAFi加SBI-0640756的组合治疗都能显著抑制肿瘤的生长。
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	H2O : Insoluble DMSO : 50 mg/mL (123.51 mM)
Keywords	Autophagy \| SBI-0640756 \| Inhibitor \| SBI 756 \| SBI756 \| Eukaryotic Initiation Factor (eIF) \| inhibit \| SBI0640756
Inhibitors Related	Oxyresveratrol \| Guanidine hydrochloride \| Naringin \| Taurine \| Gefitinib \| Xylitol \| Hydroxychloroquine \| Curcumin \| Stavudine \| Myricetin \| Paeonol \| Sodium 4-phenylbutyrate
Related Compound Libraries	Inhibitor Library \| Bioactive Compound Library \| Bioactive Compounds Library Max \| Autophagy Compound Library \| Kinase Inhibitor Library \| Apoptosis Compound Library \| Anti-Aging Compound Library \| NO PAINS Compound Library \| Endoplasmic Reticulum Stress Compound Library \| Reprogramming Compound Library

SBI-756|||SBI 0640756|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(12年)
注册资本	566.265100万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务